Skip to main content
SpringerLink
Log in

Therapeutic Concentrations of Metformin: A Systematic Review

  • Systematic Review
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Metformin has been available since 1957. Over 50 years later, one can legitimately question whether a clear definition of its “therapeutic concentrations” is available.

Objective

The objective of this systematic review was to establish whether or not there is a literature consensus on the “therapeutic concentrations” of metformin.

Methods

We systematically searched the scientific literature with the keywords “metformin”, “therapeutic concentration”, “therapeutic level”, and “therapeutic range”. When the suggested values were defined by citing a literature reference, the types of studies in cited references and the concordance of data between the citations and theirs sources were studied.

Results

We identified 120 documents that reported or cited 65 different “therapeutic” plasma metformin concentrations or ranges. The values ranged from 0.129 to 90 mg/L, and the lowest and highest boundaries were 0 and 1800 mg/L. Only four original research studies determined a “therapeutic concentration”. Fifty-four publications cited previous studies as defining the therapeutic concentrations, whereas 62 publications mentioned “therapeutic concentrations” but did not even cite a supporting reference. The supporting references were mostly reviews, pharmacokinetic studies and in vitro studies. In the 54 publications that cited references, concordance between the wording of the citation and the true nature of the source data was observed in only 23 cases (42.6 %).

Limitations

Given the nature of a systematic literature search, the only possible limitation would be incomplete identification and retrieval of publications on therapeutic concentrations. An extensive study of the literature has, however, been performed by examining nearly 1000 potentially relevant publications.

Guidance for Clinical Practice

The only valid way of defining the therapeutic concentration window for metformin would be to relate dose efficacy (in terms of blood glucose control) to the corresponding plasma concentration in long-term treated patients.

Conclusions

Although metformin has been available for over 50 years and it is the key medication in first-line treatment of type 2 diabetes mellitus, major methodological and/or conceptual errors have confounded the literature on its therapeutic concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shargel L, Wu-Pong S, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 5th ed. New York: McGraw-Hill; 2005. p. 613–72.

    Google Scholar 

  2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.

    Article  PubMed  Google Scholar 

  3. Lalau JD, Arnouts P, Sharif A, De Broe ME. Metformin and other antidiabetic agents in renal failure patients. Kidney Int. 2015;87(2):308–22.

    Article  CAS  PubMed  Google Scholar 

  4. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668–75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.

    PubMed  Google Scholar 

  6. Gottlieb B, Auld WH. Metformin in treatment of diabetes mellitus. Br Med J. 1962;1(5279):680–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Frayn KN, Adnitt PI. Effects of metformin on glucose uptake by isolated diaphragm from normal and diabetic rats. Biochem Pharmacol. 1972;21(23):3153–62.

    Article  CAS  PubMed  Google Scholar 

  8. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81–98.

    Article  CAS  PubMed  Google Scholar 

  9. Pignard P. Spectrophotometric determination of N,N-dimethylbiguanide in blood and urine [in French]. Ann Biol Clin (Paris). 1962;20:325–33.

    CAS  Google Scholar 

  10. Adnitt PI, Frayn KN. Effects of metformin on glucose uptake by the isolated rat diaphragm. Br J Pharmacol. 1972;45(1):152P–3P.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Clarke BF, Ducan LJP. Biguanide treatment in the management of insulin independent (maturity-onset) diabetes: clinical experience with metformin. Res Clin Forums. 1979;1:53–63.

    Google Scholar 

  12. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683–93.

    Article  CAS  PubMed  Google Scholar 

  13. Isnard F, Laviuville M, Gut M. Pharmacocinétique de la metformine. In: Journées de Diabétologie de l’Hôtel-Dieu. Paris: Flammarion Médecine-Sciences; 1980. p. 305–12.

  14. Bruneder H, Klein HJ, Isnard F, Noel M. Fasting metformin levels in ambulatory treated diabetic patients [abstract]. Excerpta Medica 1979;ICS 481:33,82P.

  15. Mountjoy KG, Finlay GJ, Holdaway IM. Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro. J Endocrinol Invest. 1987;10(6):553–7.

    Article  CAS  PubMed  Google Scholar 

  16. Lambert H, Isnard F, Delorme N, Claude D, Bollaert PE, Straczek J, Larcan A. Physiopathological approach to pathological hyperlactatemia in the diabetic patient. Value of blood metformin [in French]. Ann Fr Anesth Reanim. 1987;6(2):88–94.

    Article  CAS  PubMed  Google Scholar 

  17. Tymms DJ, Leatherdale BA. Lactic acidosis due to metformin therapy in a low risk patient. Postgrad Med J. 1988;64(749):230–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wollen N, Bailey CJ. Metformin potentiates the antigluconeogenic action of insulin. Diabete Metab. 1988;14(2):88–91.

    CAS  PubMed  Google Scholar 

  19. Beckmann R. Biguanide (Experimenteller Teil). In: Maske H, editor. Handbook of experimental pharmacology, vol. 29. Berlin: Springer; 1971. p. 439–596.

    Google Scholar 

  20. Noel M. Kinetic study of normal and sustained release dosage forms of metformin in normal subjects. Res Clin Forums. 1979;1:33–44.

    Google Scholar 

  21. Caporicci D, Mori A, Pepi R, Lapi E. Effects of dimethylbiguanide (metformin) on peripheral insulin clearance and lipid biosynthesis in obese dyslipidemic subjects with and without diabetes mellitus [in Italian. Clin Ter. 1979;88(4):372–86.

    CAS  PubMed  Google Scholar 

  22. De Lorenzi F. La farmacocinetica e la farmacodinamica delle biguanide [in Italian]. Omnia Med Ther. 1975;56.

  23. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol. 1988;37(22):4353–8.

    Article  CAS  PubMed  Google Scholar 

  24. Bailey CJ, Nattrass M. Treatment–metformin. Baillieres Clin Endocrinol Metab. 1988;2(2):455–76.

    Article  CAS  PubMed  Google Scholar 

  25. Gregorio F, Filipponi P, Ambrosi F, Cristallini S, Marchetti P, Calafiore R, et al. Metformin potentiates B-cell response to high glucose: an in vitro study on isolated perfused pancreas from normal rats. Diabete Metab. 1989;15(3):111–7.

    CAS  PubMed  Google Scholar 

  26. Benzi L, Marchetti P, Cecchetti P, Navalesi R. Determination of metformin and phenformin in human plasma and urine by RP-HPLC. J Chromatgr Biomed Appl. 1986;48:184–9.

    Article  Google Scholar 

  27. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol. 1990;39(11):1831–4.

    Article  CAS  PubMed  Google Scholar 

  28. Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: an assessment of metformin. Int J Clin Pharmacol Ther Toxicol. 1990;28(8):329–32.

    CAS  PubMed  Google Scholar 

  29. Gregorio F, Ambrosi F, Cristallini S, Marchetti P, Navalesi R, Brunetti P, et al. Do metformin and phenformin potentiate differently B-cell response to high glucose? An in vitro study on isolated rat pancreas. Diabete Metab. 1991;17(1):19–28.

    CAS  PubMed  Google Scholar 

  30. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981;12(2):235–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest. 1992;90(4):1386–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195–202.

    Article  PubMed  Google Scholar 

  33. Freisleben HJ, Ruckert S, Wiernsperger N, Zimmer G. The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. An electron paramagnetic resonance spectroscopic study. Biochem Pharmacol. 1992;43(6):1185–94.

    Article  CAS  PubMed  Google Scholar 

  34. Bailey CJ, Wilcock C, Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol. 1992;105(4):1009–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15(6):755–72.

    Article  CAS  PubMed  Google Scholar 

  36. Sum CF, Webster JM, Johnson AB, Catalano C, Cooper BG, Taylor R. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Med. 1992;9(1):61–5.

    Article  CAS  PubMed  Google Scholar 

  37. Hermann LS, Melander A. Biguanides: Basic aspects and clinical uses. In: Alberti KGM, DeFronzo RA, Keen H, Zimmet P, editors. International textbook of diabetes mellitus, vol. 1. London: Wiley; 1992. p. 773–95.

    Google Scholar 

  38. Marchetti P, Benzi L, Cecchetti P, Giannarelli R, Boni C, Ciociaro D, et al. Plasma biguanide levels are correlated with metabolic effects in diabetic patients. Clin Pharmacol Ther. 1987;41(4):450–4.

    Article  CAS  PubMed  Google Scholar 

  39. Marchetti P, Benzi L, Gregorio F, Giannarelli R, Cecchetti P, Di Cianni G, et al. New findings on the metabolic effects of biguanides. In vitro and in vivo studies. Minerva Endocrinol. 1988;13(3):173–80.

    CAS  PubMed  Google Scholar 

  40. Chalmers J, McBain AM, Brown IRF, Campbell IW. Metformin: Is its use contraindicated in the elderly? Pract Diab Int. 1992;9:51–3.

    Article  Google Scholar 

  41. Bailey CJ. Metformin revisited: its actions and indications for use. Diabetic Med. 1988;5:315–20.

    Article  CAS  PubMed  Google Scholar 

  42. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia. 1994;37(8):826–32.

    Article  CAS  PubMed  Google Scholar 

  43. Denno KM, Sadler TW. Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology. 1994;49(4):260–6.

    Article  CAS  PubMed  Google Scholar 

  44. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet. 1989;16(2):100–28.

    Article  CAS  PubMed  Google Scholar 

  45. Fischer Y, Thomas J, Rösen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology. 1995;136(2):412–20.

    CAS  PubMed  Google Scholar 

  46. Bailey CJ. Metformin—an update. Gen Pharmacol. 1993;24(6):1299–309.

    Article  CAS  PubMed  Google Scholar 

  47. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18(6):779–84.

    Article  CAS  PubMed  Google Scholar 

  48. Miao J, Smoak IW. In vitro effects of the biguanide metformin on early-somite mouse embryos. Toxic Subst Mech. 1995;14(3):185–92.

    CAS  Google Scholar 

  49. Wiernsperger N. Biguanides: preclinical pharmacology. In: Kuhlman J, editor. Handbook of experimental pharmacology, vol. 119. New York: Springer; 1996. p. 305–58.

    Google Scholar 

  50. Stith BJ, Goalstone ML, Espinoza R, Mossel C, Roberts D, Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology. 1996;137(7):2990–9.

    CAS  PubMed  Google Scholar 

  51. Sasson S, Gorowits N, Joost HG, King GL, Cerasi E, Kaiser N. Regulation by metformin of the hexose transport system in vascular endothelial and smooth muscle cells. Br J Pharmacol. 1996;117(6):1318–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Marchetti P, Gregorio F, Benzi L, Giannarelli R, Cecchetti P, Villani G, et al. Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients. Diabete Metab. 1990;16(6):473–8.

    CAS  PubMed  Google Scholar 

  53. Caillé G, Lacasse Y, Raymond M, Landriault H, Perrotta M, Picirilli G, et al. Bioavailability of metformin in tablet form using a new high pressure liquid chromatography assay method. Biopharm Drug Dispos. 1993;14(3):257–63.

    Article  PubMed  Google Scholar 

  54. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30(5):359–71.

    Article  CAS  PubMed  Google Scholar 

  55. Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997;46(9):1406–13.

    Article  CAS  PubMed  Google Scholar 

  56. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie. 1997;52(12):895–911.

    CAS  PubMed  Google Scholar 

  57. Stith BJ, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol. 1998;55(4):533–6.

    Article  CAS  PubMed  Google Scholar 

  58. Lalau JD, Mourlhon C, Bergeret A, Lacroix C. Consequences of metformin intoxication. Diabetes Care. 1998;21(11):2036–7.

    Article  CAS  PubMed  Google Scholar 

  59. Lalau JD, Race JM, Brinquin L. Lactic acidosis in metformin therapy. Relationship between plasma metformin concentration and renal function. Diabetes Care. 1998;21(8):1366–7.

    Article  CAS  PubMed  Google Scholar 

  60. al-Jebawi AF, Lassman MN, Abourizk NN. Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care. 1998;21(8):1364–5.

    Article  CAS  PubMed  Google Scholar 

  61. Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes. Diabetologia. 1998;41(1):2–8.

    Article  CAS  PubMed  Google Scholar 

  62. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.

    Article  CAS  PubMed  Google Scholar 

  63. Detaille D, Wiernsperger N, Devos P. Cellular and molecular mechanisms involved in insulin’s potentiation of glycogen synthase activity by metformin. Biochem Pharmacol. 1999;58(9):1475–86.

    Article  CAS  PubMed  Google Scholar 

  64. Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol. 1999;364(2–3):205–9.

    Article  CAS  PubMed  Google Scholar 

  65. Wiernsperger NF. Membrane physiology as a basis for the cellular effects of metformin in insulin resistance and diabetes. Diabetes Metab. 1999;25(2):110–27.

    CAS  PubMed  Google Scholar 

  66. Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs. 1999;58(Suppl 1):55–60.

    Article  CAS  PubMed  Google Scholar 

  67. Nelson RW. Oral medications for treating diabetes mellitus in dogs and cats. J Small Anim Pract. 2000;41(11):486–90.

    Article  CAS  PubMed  Google Scholar 

  68. Sambol NC, Chiang J, O’Conner M, Liu CY, Lin ET, Goodman AM, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996;36(11):1012–21.

    Article  CAS  PubMed  Google Scholar 

  69. Desel H, Stedtler U, Behrens A, Neuratz H. Mischintoxikation mit Metformin. Toxichem Krimtech [in German]. 2000;67:4–8.

    Google Scholar 

  70. Reeker W, Schneider G, Felgenhauer N, Tempel G, Kochs E. Metformin-inducedlactic acidosis [in German]. Dtsch Med Wochenschr. 2000;125:249–51.

    Article  CAS  PubMed  Google Scholar 

  71. Lipha Pharmaceuticals Inc. Package insert of Glucophage [FDA approved]. France: Lipha Pharmaceuticals Inc.; 1997.

    Google Scholar 

  72. Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab. 2000;2(3):131–7.

    Article  CAS  PubMed  Google Scholar 

  73. Mueller WM, Stanhope KL, Gregoire F, Evans JL, Havel PJ. Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res. 2000;8(7):530–9.

    Article  CAS  PubMed  Google Scholar 

  74. Lalau JD, Race JM, Andreelli F, Lacroix C, Canarelli JP. Metformin retention independent of renal failure in intestinal occlusion. Diabetes Metab. 2001;27(1):24–8.

    CAS  PubMed  Google Scholar 

  75. Kruse JA. Metformin-associated lactic acidosis. J Emerg Med. 2001;20(3):267–72.

    Article  CAS  PubMed  Google Scholar 

  76. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab. 2001;3(3):195–201.

    Article  CAS  PubMed  Google Scholar 

  77. Yuan L, Ziegler R, Hamann A. Inhibition of phosphoenolpyruvate carboxykinase gene expression by metformin in cultured hepatocytes. Chin Med J. 2002;115(12):1843–8.

    CAS  PubMed  Google Scholar 

  78. Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patanè G, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes. 2002;51(Suppl 1):S134–7.

    Article  CAS  PubMed  Google Scholar 

  79. Barrueto F, Meggs WJ, Barchman MJ. Clearance of metformin by hemofiltration in overdose. J Toxicol Clin Toxicol. 2002;40(2):177–80.

    Article  PubMed  Google Scholar 

  80. Lalau JD, Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes Metab. 2003;5(2):93–8.

    Article  CAS  PubMed  Google Scholar 

  81. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447–74.

    CAS  PubMed  Google Scholar 

  82. Nisse P, Mathieu-Nolf M, Deveaux M, Forceville X, Combes A. A fatal case of metformin poisoning. J Toxicol Clin Toxicol. 2003;41(7):1035–6.

    Article  PubMed  Google Scholar 

  83. Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care. 2003;26(8):2471–2.

    Article  PubMed  Google Scholar 

  84. Sweeney D, Raymer ML, Lockwood TD. Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. Biochem Pharmacol. 2003;66(4):663–77.

    Article  CAS  PubMed  Google Scholar 

  85. Howlett HC, Bailey C. A risk-benefit analysis of metformin in type-2 diabetes mellitus. Drug Saf. 2001;6:489–503.

    Google Scholar 

  86. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res. 1994;30(3):187–228.

    Article  CAS  PubMed  Google Scholar 

  87. Moore KA, Levine B, Titus JM, Fowler DR. Analysis of metformin in antemortem serum and postmortem specimens by a novel HPLC method and application to an intoxication case. J Anal Toxicol. 2003;27(8):592–4.

    Article  CAS  PubMed  Google Scholar 

  88. Nelson R, Spann D, Elliott D, Brondos A, Vulliet R. Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats. J Vet Intern Med. 2004;18(1):18–24.

    Article  PubMed  Google Scholar 

  89. Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J. 2004;382(Pt 3):877–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Feng SY, Lai EP, Dabek-Zlotorzynska E, Sadeghi S. Molecularly imprinted solid-phase extraction for the screening of antihyperglycemic biguanides. J Chromatogr A. 2004;1027(1–2):155–60.

    Article  CAS  PubMed  Google Scholar 

  91. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255(2):179–87.

    Article  CAS  PubMed  Google Scholar 

  92. Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ. Metformin (glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004;67(11):2081–91.

    Article  CAS  PubMed  Google Scholar 

  93. Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–41.

    Article  CAS  PubMed  Google Scholar 

  94. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000;49(5):735–40.

    Article  PubMed  Google Scholar 

  95. Lalau JD, Masmoudi K. Unexpected recovery from prolonged hypoglycemic coma: a protective role of metformin? [letter]. Intensive Care Med. 2005;31(3):493.

    Article  PubMed  Google Scholar 

  96. Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54(7):2179–87.

    Article  CAS  PubMed  Google Scholar 

  97. Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22(2):255–9.

    Article  CAS  PubMed  Google Scholar 

  98. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110.

    Article  CAS  PubMed  Google Scholar 

  99. Arafat T, Kaddoumi A, Shami M, Yassin M. Pharmacokinetics and pharmacodynamics of two oral formulations of metformin hydrochloride. Adv Ther. 1994;11:21–33.

    Google Scholar 

  100. Brookes LG, Sambol NC, Lin ET, et al. Effect of dosage for dose and food on the pharmacokinetics of metformin [abstract]. Pharm Res. 1991;8(Suppl.):S320.

    Google Scholar 

  101. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35(11):1094–102.

    Article  CAS  PubMed  Google Scholar 

  102. Lacher M, Hermanns-Clausen M, Haeffner K, Brandis M, Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr. 2005;164(6):362–5.

    Article  PubMed  Google Scholar 

  103. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26(3):611–7.

    Article  CAS  PubMed  Google Scholar 

  104. Friesecke S, Abel P, Kraft M, Gerner A, Runge S. Combined renal replacement therapy for severe metformin-induced lactic acidosis. Nephrol Dial Transplant. 2006;21(7):2038–9.

    Article  PubMed  Google Scholar 

  105. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91(1):225–7.

    Article  CAS  PubMed  Google Scholar 

  106. Del Prato S, Bianchi C, Marchetti P. beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab Res Rev. 2007;23(7):518–27.

    Article  PubMed  CAS  Google Scholar 

  107. Wessler I, Herschel S, Bittinger F, Kirkpatrick CJ. Release of non-neuronal acetylcholine from the isolated human placenta is affected by antidepressants. Life Sci. 2007;80(24–25):2210–3.

    Article  CAS  PubMed  Google Scholar 

  108. Prikis M, Mesler EL, Hood VL, Weise WJ. When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis. Kidney Int. 2007;72(9):1157–60.

    Article  CAS  PubMed  Google Scholar 

  109. Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Br J Anaesth. 2007;98(2):213–5.

    Article  CAS  PubMed  Google Scholar 

  110. Bruijstens LA, van Luin M, Buscher-Jungerhans PM, Bosch FH. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med. 2008;66(5):185–90.

    CAS  PubMed  Google Scholar 

  111. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med. 2009;37(7):2191–6.

    Article  CAS  PubMed  Google Scholar 

  112. Dell’Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD, Morgan BW. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med. 2009;54(6):818–23.

    Article  PubMed  Google Scholar 

  113. Stambolic V, Woodgett JR, Fantus IG, Pritchard KI, Goodwin PJ. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor? Breast Cancer Res Treat. 2009;114(2):387–9.

    Article  PubMed  Google Scholar 

  114. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.

    Article  CAS  PubMed  Google Scholar 

  115. Cunha JP, editor. Fortamet (metformin HCl) monograph. RxList [updated 2013 November 20]. 2013 http://www.rxlist.com/cgi/generic/fortamet_cp.htm. Accessed 15 June 2014.

  116. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33(9):727–40.

    Article  CAS  PubMed  Google Scholar 

  117. Friesecke S, Abel P, Roser M, Felix SB, Runge S. Outcome of severe lactic acidosis associated with metformin accumulation. Crit Care. 2010;14(6):R226.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Kane DA, Anderson EJ, Price JW, Woodlief TL, Lin CT, Bikman BT, et al. Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese rats. Free Radic Biol Med. 2010;49(6):1082–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E, Andersson A. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33(6):1291–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Giuliani E, Albertini G, Vaccari C, Barbieri A. pH 6.68—surviving severe metformin intoxication. QJM. 2010;103(11):887–90.

    Article  CAS  PubMed  Google Scholar 

  121. Protti A, Russo R, Tagliabue P, Vecchio S, Singer M, Rudiger A, et al. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care. 2010;14(1):R22.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Dell’Aglio DM, Perino LJ, Todino JD, Algren DA, Morgan BW. Metformin overdose with a resultant serum pH of 6.59: survival without sequalae. J Emerg Med. 2010;39(1):e77–80.

    Article  PubMed  Google Scholar 

  123. Sørensen LK. Determination of metformin and other biguanides in forensic whole blood samples by hydrophilic interaction liquid chromatography-electrospray tandem mass spectrometry. Biomed Chromatogr. 2012;26(1):1–5.

    Article  PubMed  CAS  Google Scholar 

  124. The International Association of Forensic Toxicologists (TIAFT). Reference blood level list of therapeutic and toxic substances. London: The Association; 1995–2015. http://www.tiaft.org. Accessed 8 Dec 2010.

  125. Yeung CW, Chung HY, Fong BM, Tsai NW, Chan WM, Siu TS, et al. Metformin-associated lactic acidosis in Chinese patients with type II diabetes. Pharmacology. 2011;88(5–6):260–5.

    Article  CAS  PubMed  Google Scholar 

  126. Lalau JD, Lemaire-Hurtel AS, Lacroix C. Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations. Clin Drug Investig. 2011;31(6):435–8.

    Article  CAS  PubMed  Google Scholar 

  127. de Oliveira Baraldi C, Lanchote VL, de Jesus Antunes N, de Jesus Ponte Carvalho TM, Dantas Moisés EC, Duarte G, et al. Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. Eur J Clin Pharmacol. 2011;67(10):1027–33.

    Article  PubMed  CAS  Google Scholar 

  128. Correia CS, Bronander KA. Metformin-associated lactic acidosis masquerading as ischemic bowel. Am J Med. 2012;125(5):e9.

    Article  PubMed  Google Scholar 

  129. Vecchio S, Papa P, Protti A. Metformin and lactic acidosis. In: Vincent JL, editor. Annual update in intensive care and emergency medicine, vol. 1. Heidelberg: Springer Science & Business Media; 2011. p. 685–93.

    Google Scholar 

  130. Takiyama Y, Harumi T, Watanabe J, Fujita Y, Honjo J, Shimizu N, Makino Y, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism. Diabetes. 2011;60(3):981–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574–9.

    Article  CAS  PubMed  Google Scholar 

  132. Roche C, Nau A, Peytel E, Moalic JL, Oliver M. Severe lactic acidosis due to metformin: report of 3 cases. Ann Biol Clin (Paris). 2011;69(6):705–11.

    Google Scholar 

  133. Perrone J, Phillips C, Gaieski D. Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011;40(3):271–5.

    Article  PubMed  Google Scholar 

  134. Pikwer A, Vernersson E, Frid A, Sterner G. Extreme lactic acidosis type B associated with metformin treatment. NDT Plus. 2011;4(6):399–401.

    PubMed  PubMed Central  Google Scholar 

  135. Cosenza L, Al-Dahir S, Engel LS, Nielsen N. A potentially fatal case of mistaken identity: metformin vs oxycodone-acetaminophen [abstract]. J Investig Med. 2011;59(2):385.

    Google Scholar 

  136. Berstein LM, Yue W, Wang JP, Santen RJ. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells. Breast Cancer Res Treat. 2011;128(1):109–17.

    Article  CAS  PubMed  Google Scholar 

  137. Jagia M, Taqi S, Hanafi M. Metformin poisoning: a complex presentation. Indian J Anaesth. 2011;55(2):190–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Briet C, Saraval-Gross M, Kajbaf F, Fournier A, Hary L, Lalau JD. Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Clin Kidney J. 2012;5(1):65–7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  139. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care. 2012;16(4):R136.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Protti A, Fortunato F, Monti M, Vecchio S, Gatti S, Comi GP, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care. 2012;16(3):R75.

    Article  PubMed  PubMed Central  Google Scholar 

  141. Protti A, Lecchi A, Fortunato F, Artoni A, Greppi N, Vecchio S, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care. 2012;16(5):R180.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Lam N, Sekhon G, House AA. Metformin-associated lactic acidosis following intentional overdose successfully treated with tris-hydroxymethyl aminomethane and renal replacement therapy. Case Rep Nephrol. 2012;2012:671595.

    PubMed  PubMed Central  Google Scholar 

  143. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43.

    Article  CAS  PubMed  Google Scholar 

  144. Duong JK, Furlong TJ, Roberts DM, Graham GG, Greenfield JR, Williams KM, et al. The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf (Epub 2013 Apr 3).

  145. Kajbaf F, Lalau JD. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med. 2013;30(3):345–8.

    Article  CAS  PubMed  Google Scholar 

  146. Luft D, Deichsel G, Schmulling R, et al. Definition of clinically relevant lactic acidosis in patients with internal diseases. Am J Clin Pathol. 1983;80(4):484–9.

    CAS  PubMed  Google Scholar 

  147. Kajbaf F, Lalau JD. The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis. BMC Pharmacol Toxicol. 2013;12(14):22.

    Article  CAS  Google Scholar 

  148. Bonsignore A, Pozzi F, Fraternali Orcioni G, Ventura F, Palmiere C. Fatal metformin overdose: case report and postmortem biochemistry contribution. Int J Legal Med. 2014;128(3):483–92.

    Article  PubMed  Google Scholar 

  149. Al-Abri SA, Hayashi S, Thoren KL, Olson KR. Metformin overdose-induced hypoglycemia in the absence of other antidiabetic drugs. Clin Toxicol (Phila). 2013;51(5):444–7.

    Article  CAS  Google Scholar 

  150. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185–210.

    Article  CAS  PubMed  Google Scholar 

  152. Vecchio S, Giampreti A, Petrolini VM, Lonati D, Protti A, Papa P, Rognoni C, et al. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila). 2014;52(2):129–35.

    Article  CAS  Google Scholar 

  153. Moffat AC, Osselton MD, Widdop B, editors. Clarke’s analysis of drugs and poisons. 3rd ed. London: Pharmaceutical Press; 2004. p. 243.

    Google Scholar 

  154. Repetto MR, Repetto M. Tabla de concentraciones de xenobioticos en fluidos humanos como referencia parael diagnostico toxicologico. 2012. http://www.busca-tox.com. Accessed 3 July 2012.

  155. Geerling JJ, Boon MR, van der Zon GC, van den Berg SA, van den Hoek AM, Lombès M, et al. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes. 2014;63(3):880–91.

    Article  CAS  PubMed  Google Scholar 

  156. Launiainen T, Ojanperä I. Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma. Drug Test Anal. 2014;6(4):308–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  157. Fremin K, Owen J. Metformin overdose and early renal replacement therapy. Am J Kidney Dis. 2014;63(5):B47.

    Google Scholar 

  158. Renehan A. Diabetes treatment and cancer—five years after the ‘breaking news’. Diabetes Voice. 2014;59(1):36–9.

    Google Scholar 

  159. Adam WR, O’Brien RC. A justification for less restrictive guidelines on the use of metformin in stable chronic renal failure. Diabet Med. 2014;31(9):1032–8.

    Article  CAS  PubMed  Google Scholar 

  160. Acquistapace G, Rossi M, Garbi M, Cosci P, Canetta C, Manelli A, et al. Acute metformin intoxication: 2012 experience of Emergency Department of Lodi, Italy. Clin Chem Lab Med. 2014;52(10):1489–97.

    Article  CAS  PubMed  Google Scholar 

  161. Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37(3):876–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  162. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299–306.

    Article  CAS  PubMed  Google Scholar 

  163. Goswami S, Yee SW, Stocker S, Mosley JD, Kubo M, Castro R, et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2014;96(3):370–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011;21(12):837–50.

    Article  CAS  PubMed  Google Scholar 

  165. Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S. Global Partnership for Effective Diabetes Management. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res. 2013;10(5):397–409.

    Article  CAS  PubMed  Google Scholar 

  166. Watanabe RM. Drugs, diabetes and pharmacogenomics: the road to personalized therapy. Pharmacogenomics. 2011;12(5):699–701.

    Article  PubMed  Google Scholar 

  167. Esposito K, Ceriello A, Giugliano D. Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine. 2013;44(2):343–5.

    Article  CAS  PubMed  Google Scholar 

  168. Ceriello A, Gallo M, Candido R, De Micheli A, Esposito K, Gentile S, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med. 2014;19(7):129–36.

    Google Scholar 

  169. Scheen AJ. Personalising metformin therapy: a clinician’s perspective. Lancet Diabetes Endocrinol. 2014;2(6):442–4.

    Article  PubMed  Google Scholar 

  170. Pratley RE, Kuritzky L, Tenzer P. A patient-centered approach to managing patients with type 2 diabetes. Am J Med. 2014;127(11):e15–6.

    Article  PubMed  Google Scholar 

  171. Cao J, Meng S, Chang E, Beckwith-Fickas K, Xiong L, Cole RN, et al. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J Biol Chem. 2014;289(30):20435–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. El-Mir MY, Nogueira V, Fontaine E, Ave´ret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–8.

    Article  CAS  PubMed  Google Scholar 

  173. Piel S, Ehinger JK, Elmér E, Hansson MJ. Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol (Oxf). 2015;213(1):171–80.

    Article  CAS  PubMed  Google Scholar 

  174. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Lalau JD, Kajbaf F. Interpreting the consequences of metformin accumulation in an emergency context: impact of the time frame on the blood metformin levels. Int J Endocrinol. 2014;2014:717198.

    Article  PubMed  PubMed Central  Google Scholar 

  176. Lalau JD, Azzoug ML, Kajbaf F, Briet C, Desailloud R. Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. Diabetes Metab. 2014;40(3):220–3.

    Article  CAS  PubMed  Google Scholar 

  177. Kajbaf F, Lalau JD, Azzoug M, Lemaire-Hurtel AS, De Broe ME. Metformin therapy at different stages of chronic kidney disease [abstract]. J Am Soc Nephrol. 2014;25(Abstract Edition):76A.

    Google Scholar 

Download references

Acknowledgments

The authors thank the Amiens University Library and Dr Kerstin Brand for providing reprints of some articles.

Author information

Authors and Affiliations

  1. Department of Endocrinology-Nutrition, University Hospital, Amiens, France

    Farshad Kajbaf & Jean-Daniel Lalau

  2. INSERM 1088, University of Picardie Jules Verne, Amiens, France

    Farshad Kajbaf & Jean-Daniel Lalau

  3. Laboratory of Pathophysiology, University of Antwerp, Wilrijk, Belgium

    Marc E. De Broe

Authors
  1. Farshad Kajbaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc E. De Broe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Daniel Lalau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Daniel Lalau.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kajbaf, F., De Broe, M.E. & Lalau, JD. Therapeutic Concentrations of Metformin: A Systematic Review. Clin Pharmacokinet 55, 439–459 (2016). https://doi.org/10.1007/s40262-015-0323-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0323-x

Keywords

Search

Navigation